Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19406054 | 0.84 | POLB (0.34) | GPR119POLBNPC1MEN1KMT2A | |
| SCHEMBL9895355 | 0.75 | PIK3CG (0.45) | NPC1MEN1KMT2AAPPTHRB | |
| SCHEMBL19405832 | 0.73 | ACACA (0.43) | GPR119ACACB | |
| SCHEMBL23628683 | 0.67 | S1PR1 (0.35) | — | |
| SCHEMBL11920525 | 0.65 | ESR2 (0.47) | USP14 | |
| SCHEMBL19406029 | 0.65 | GAA (0.47) | POLBNPC1MEN1KMT2AUSP14 | |
| SCHEMBL21492947 | 0.65 | USP14 (0.37) | POLBNPC1KMT2ALMNAUSP14 | |
| SCHEMBL21493197 | 0.64 | BACE1 (0.34) | POLBKMT2AUSP14 | |
| SCHEMBL27150670 | 0.64 | TEC (0.35) | CA12CA1CA9USP14 | |
| SCHEMBL31430559 | 0.64 | IL6 (0.39) | POLBNPC1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002322-A1 | BICYCLIC COMPOUND | ACACA, ACACB, ACAT1 | GPR119 2265/4885POLB 984/4885NPC1 445/4885 |
| US-10301292-B2 | Bicyclic compound | ACACA, ACACB, ACAT1 | GPR119 2265/4885POLB 984/4885NPC1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.